Canine Atopic Dermatitis Market Worth $1.8 Billion By 2027

The global canine atopic dermatitis market size is expected to reach USD 1.8 billion by 2027, expanding at a CAGR of 9.0% over the forecast period, according to a new report by Grand View Research, Inc. Increasing prevalence of the disease and growing companion ownership are the key factors driving the market growth.

Growing concern among pet owners regarding their pet’s health is further propelling the market growth. According to American Academy of Physician Assistants (AAPA), U.S. pet owners spent around USD 7.4 billion on pet care in 2017 whereas, Europe spent around USD 6.1 billion. The anticipated rise in dog ownership is expected to increase the demand for better treatment facilities.

According to The American Pet Products Association report 2018, veterinary care spending increased by 7% from USD 15.95 billion in 2016 to USD 17.07 billion in 2017. An increase in the number of veterinary clinic visits is further boosting the canine atopic dermatitis market growth. According to the American Veterinary Medical Association (AVMA) report, as of 2018, around 70% dog owners usually go to veterinary hospitals or clinics for the routine check-up of their pets. These aforementioned factors are expected to fuel the growth of the canine atopic dermatitis treatment market over the forecast period.

Full Research Report On Canine Atopic Dermatitis Market Visit Here: https://www.grandviewresearch.com/industry-analysis/canine-atopic-dermatitis-treatment-market

Further key findings from the report suggest:

• On the basis of product, the Monoclonal Antibodies (MAbs) segment is projected to register a CAGR of 16.1% over the forecast period owing to increased efficacy and strong product pipeline
• Based on mode of administration, the oral segment held the largest share as of 2019 owing to low cost and ease of administration
• On the basis of distribution channel, the retail segment held the largest share as of 2019, owing to ever rising footprint of retail pharmacies and product availability
• By region, Asia Pacific is expected to exhibit the highest growth rate over the forecast period due to increase in disposable income and growing companion ownership
• Some of the key companies in the canine atopic dermatitis market are Zoetis, Elanco, Toray Industries, and Virbac.

Request a Sample Copy of the Report @ https://www.grandviewresearch.com/industry-analysis/canine-atopic-dermatitis-treatment-market/request/rs1

Grand View Research has segmented the global canine atopic dermatitis market on the basis of product, mode of administration, distribution channel, and region:

Canine Atopic Dermatitis Treatment Product Outlook (Revenue, USD Million, 2016 - 2027)

• Glucocorticoids
• Antihistamines
• Immunosuppressants
• MAbs
• Others

Canine Atopic Dermatitis Treatment Mode of Administration Outlook (Revenue, USD Million, 2016 - 2027)

• Topical
• Oral
• Injectable

Canine Atopic Dermatitis Treatment Distribution Channel Outlook (Revenue, USD Million, 2016 - 2027)

• Veterinary Hospitals/Clinics
• Retail
• E-commerce

Canine Atopic Dermatitis Treatment Regional Outlook (Revenue, USD Million, 2016 - 2027)

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• France
• Italy
• Spain
• Russia
• Asia Pacific
• Japan
• China
• India
• Australia
• Latin America
• Brazil
• Mexico
• Argentina
• Middle East & Africa
• South Africa
• Saudi Arabia

About Grand View Research        

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more info visit @ https://www.grandviewresearch.com

 

Viral Vectors & Plasmid DNA Manufacturing Market Size Is Estimated To Reach $1.1 Billion By 2027

The global viral vectors & plasmid DNA manufacturing market size is expected to reach USD 1.1 billion by 2027, exhibiting a 14.52% CAGR, during the forecast period, according to a new report by Grand View Research, Inc. Currently, more than 700 cell and gene therapies are in clinical trials and vectors are used in nearly 70% of these therapies. As a result, demand for vectors has exceeded the supply rate. Thus, an increase in the number of advanced therapy-based discovery programs initiated by biotechnology and pharmaceutical companies is expected to drive investments in the market.

Current production methods for viral vectors are considered tedious, as they are only applicable for scale-out but not for scale-up. Development of a proprietary CAP-GT technology-based cell suspension system by CEVEC Pharmaceuticals GmbH has effectively addressed the challenge of scaling-up by allowing easy handling and improved efficiency of cells.

Considering growing opportunities in vector production, the Original Equipment Manufacturers (OEMs) are making focused efforts to gain a competitive advantage in the market. For example, the introduction of ready-to-run factory-in-a-box to accelerate the production of virus-based therapeutics by GE healthcare, as a solution to simplify and advance the manufacturing process.

Full Research Report On Viral Vectors & Plasmid DNA Manufacturing Market Visit Here: https://www.grandviewresearch.com/industry-analysis/viral-vector-manufacturing-market

Viral Vectors & Plasmid DNA Manufacturing Market Report Highlights

• With high usage, attributed to its ability of high titer production and capability to induce strong humoral and T cell responses in various research applications, adenovirus held the leading viral vectors and plasmid DNA manufacturing market share in terms of revenue, in 2019
• Lentivirus vector is anticipated to register the fastest CAGR over the forecast period. This can be attributed to constant growth in the lentivirus-based gene therapy pipeline program
• Downstream processing held the dominant revenue share in 2019, owing to the fact that this process involves purification steps that account for the majority of the overall manufacturing cost. Employment of expensive equipment and requirement of trained personnel for product recovery has further driven revenue in the segment
• Antisense and RNAi therapy production is estimated as the key application of vector manufacturing, resulting in the dominance of this segment over other applications
• The high adoption rate of viruses for aptamers and oligonucleotide development in comparison to other applications has driven revenue in antisense and RNAi therapy segment
• High usage of vectors for therapeutic production have contributed to the large revenue share of pharmaceutical and biopharmaceutical companies. The number of biotech companies employing vector for therapies production is anticipated to multiply over the forecast period
• Presence of a substantial number of advanced therapy products in the pipeline targeting various cancer forms has accelerated revenue share of the cancer segment over the years
• Given the high number of biotech entities in parts of U.S., such as in California and Massachusetts, North America has maintained its dominance in terms of revenue. In addition, the active participation of regulatory bodies in improving the regulatory scenario for the market launch of advanced therapies has facilitated the high usage of vectors in U.S.
• Merck, Cobra Biologics, Novasep, and uniQure N.V., are some key participants that are geared towards capitalizing the untapped opportunities in the market

Request a Sample Copy of the Report @ https://www.grandviewresearch.com/industry-analysis/viral-vector-manufacturing-market/request/rs1

Viral Vectors & Plasmid DNA Manufacturing Market Segmentation

Grand View Research has segmented the global viral vectors and plasmid DNA manufacturing market on the basis of vector type, workflow, application, end use, disease, and region:

Viral Vector and Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Million, 2016 - 2027)

• Adenovirus
• Retrovirus
• Plasmid DNA
• AAV
• Lentivirus
• Others

Viral Vector and Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Million, 2016 - 2027)

• Upstream Processing
• Vector Amplification & Expansion
• Vector Recovery/Harvesting
• Downstream Processing
• Purification
• Fill-finish

Viral Vector and Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2016 - 2027)

• Antisense & RNAi
• Gene Therapy
• Cell Therapy
• Vaccinology

Viral Vector and Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Million, 2016 - 2027)

• Pharmaceutical and Biopharmaceutical Companies
• Research Institutes

Viral Vector and Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2016 - 2027)

• Cancer
• Genetic Disorders
• Infectious Diseases
• Others

Viral Vector and Plasmid DNA Manufacturing Regional Outlook (Revenue, USD Million, 2016 - 2027)

• North America
• U.S.
• Canada
• Europe
• Germany
• U.K.
• Asia Pacific
• China
• Japan
• Latin America
• Brazil
• Middle East & Africa
• South Africa

About Grand View Research        

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more info visit @ https://www.grandviewresearch.com

 

Muscle Stimulator Market Size Is Projected To Reach $910.2 Million By 2027

The global muscle stimulator market size is anticipated to reach USD 910.2 million by 2027, registering a CAGR of 3.9% over the forecast period, according to a new report by Grand View Research, Inc. The growing prevalence of musculoskeletal disorders and increasing demand for pain management therapies are the key factors driving the growth over the forecast period. Moreover, growing purchasing power, increasing healthcare expenditure, and technological innovations in medical devices are also driving the market growth.

Based on product type, Transcutaneous Electrical Nerve Stimulation (TENS) dominated the global market in 2019. Increasing demand for portable stimulation devices that can be operated at home and rising geriatric population that is prone to develop musculoskeletal disorders are the major factors driving the market growth. On the other hand, Neuromuscular Electrical Stimulation (NES) is estimated to be the fastest-growing segment during the forecast period owing to increasing cases of strokes and spinal cord injuries.

Based on modality, the market is segmented into portable, handheld, and tabletop. Portable stimulator dominated the muscle stimulator space in 2019, owing to the ease of carrying them while traveling and higher purchasing power in the hands of consumers. The segment is also anticipated to grow at the fastest rate of 4.2% during the forecast period. Key players launching innovative portable muscle stimulator devices to sustain market competition is also a major factor driving the segment growth.

Based on applications, the muscle stimulator market is segmented into pain management, neurological disorders, musculoskeletal disorders, and others. The pain management segment dominated the market with a share of 54.5% in 2019 and is anticipated to be the fastest growing segment during the forecast period. Increasing cases of chronic and acute pain and the need for effective pain management therapies among cancer patients are the major factors driving the growth over the forecast period.

Full Research Report On Muscle Stimulator Market Visit Here: https://www.grandviewresearch.com/industry-analysis/muscle-stimulator-market

Muscle Stimulator Market Report Highlights

• The global market is anticipated to reach USD 910.2 million by 2027 owing to rising prevalence of musculoskeletal disorders and increasing demand for pain management therapies
• Transcutaneous Electrical Nerve Stimulation (TENS) dominated the muscle stimulator market in 2019, owing to an increase in the demand for portable stimulator
• Portable devices are estimated to witness the fastest growth of 4.2%, as their usage in muscle atrophy, relaxation of muscle spasms, and managing chronic pain is increasing
• In 2019, the pain management application segment dominated the market with a share of 54.5% owing to increasing usage of muscle stimulator in the management of chronic and acute pain
• Some of the notable players in the market are NeuroMetrix, Inc.; OMRON Corporation; BioMedical Life Systems, Inc.; Zynex, Inc.; EMS Physio Ltd.; DJO Global, Inc.; and Beurer GmbH.

Request a Sample Copy of the Report @ https://www.grandviewresearch.com/industry-analysis/muscle-stimulator-market/request/rs1

Muscle Stimulator Market Segmentation

Grand View Research has segmented the global muscle stimulator market based on product, modality, application, end use, and region:

Muscle Stimulator Product Outlook (Revenue, USD Million, 2016 - 2027)

• Neuromuscular Electrical Stimulation
• Functional Electrical Stimulation
• Transcutaneous Electrical Nerve Stimulation
• Interferential
• Burst Mode Alternating Current
• Micro Current Electrical Neuromuscular Stimulator
• Others

Muscle Stimulator Modality Outlook (Revenue, USD Million, 2016 - 2027)

• Handheld
• Portable
• Table Top

Muscle Stimulator Application Outlook (Revenue, USD Million, 2016 - 2027)

• Pain Management
• Neurological Disorder
• Musculoskeletal Disorder
• Others

Muscle Stimulator End Use Outlook (Revenue, USD Million, 2016 - 2027)

• Hospitals
• Ambulatory Surgical Centers
• Physiotherapy Clinics
• Sports Clinics
• Home Care

Muscle Stimulator Regional Outlook (Revenue, USD Million, 2016 - 2027)

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Asia Pacific
• Japan
• China
• India
• South Korea
• Singapore
• Australia
• Latin America
• Brazil
• Mexico
• MEA
• South Africa
• Saudi Arabia
• UAE

About Grand View Research        

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more info visit @ https://www.grandviewresearch.com

 

Legal Marijuana Market Size Is Estimated To Reach $73.6 Billion By 2027

The global legal marijuana market size is expected to reach USD 73.6 billion by 2027, according to a new report published by Grand View Research, Inc. It is anticipated to expand at a CAGR of 18.1% during the forecast period. The increasing legalization of cannabis for medical as well as adult-use is expected to promote growth.

On the basis of type, the medical segment held the leading revenue share of 71.0% in 2019, owing to the growing adoption of cannabis as a pharmaceutical product for treating severe medical conditions, such as cancer, arthritis, and Parkinson’s disease, and Alzheimer’s disease among other neurological conditions. Moreover, the increasing need for pain management therapies along with the growing disease burden of chronic pain among elders is expected to boost the product demand.

Based on product type, the legal marijuana buds segment accounted for the largest market share in terms of revenue and was valued at USD 9.1 billion in 2019. Buds are primary plant products and are readily available without any processing, which makes them relatively affordable for low-income patients. Moreover, the rapid onset of action of smoking buds compared to other types is anticipated to further fuel the segment growth.

Based on medical applications, the chronic pain segment dominated the legal marijuana market in 2019 owing to the presence of a large patient pool. On the other hand, mental disorder application is expected to witness the fastest growth over the forecast period owing to the growing number of patients suffering from mental disorders, such as anxiety disorder, depressions, and Alzheimer’s disease.

Based on geography, North America held the largest revenue share at 88.4% in 2019, owing to the increasing legalization of medical marijuana and liberalism of government regulations regarding the same. The legalization of medical cannabis in Canada, Israel, and some countries in Europe and South America owing to its multiple therapeutic applications is expected to promote growth. Moreover, the recent legalization of cannabis for medical purposes in countries like Australia, Germany, and Poland is expected to create lucrative opportunities for market stakeholders.

Full Research Report On Legal Marijuana Market Visit Here: https://www.grandviewresearch.com/industry-analysis/legal-marijuana-market

Further key findings from the report suggest:

• Based on marijuana type, the medical segment held the largest market share of 71.0% in 2019 owing to the increasing use of the product for the treatment of cancer and other medical conditions
• By product type, the buds segment holds the largest market share in 2019 with a revenue of USD 9.1 billion owing to the easy availability of buds than other products
• Key players operating in the legal marijuana market include Aurora Cannabis; Canopy Growth Corporation; Maricann Group, Inc.; GW Pharmaceuticals, plc.; Aphria, Inc.; Tilray; The Cronos Group; ABcann Medicinals, Inc.; Lexaria Corp.; and Organigram Holding, Inc.

Request a Sample Copy of the Report @ https://www.grandviewresearch.com/industry-analysis/legal-marijuana-market/request/rs1

Grand View Research has segmented the global legal marijuana market based on marijuana type, product type, medical application, and regional outlook:

Legal Marijuana Type Outlook (Revenue, USD Million, 2016 - 2027)

• Medical
• Adult Use

Legal Marijuana Product Type Outlook (Revenue, USD Million, 2016 - 2027)

• Buds
• Oils
• Tinctures

Legal Marijuana Medical Application Outlook (Revenue, USD Million, 2016 - 2027)

• Chronic Pain
• Mental Disorders
• Cancer
• Others

Legal Marijuana Regional Outlook (Revenue, USD Million, 2016 - 2027)

• U.S.
• Canada
• Germany
• Italy
• Netherlands
• Croatia
• Poland
• Czech Republic
• Switzerland
• Australia
• Uruguay
• Colombia
• Mexico
• Chile
• Argentina
• Israel

About Grand View Research        

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more info visit @ https://www.grandviewresearch.com